EPCAM and neoplasm: In these immunodeficient mice, EpCAM-NIR-PIT resulted in slight tumour growth suppression compared to the control and AbPC intravenous injection-only groups (Figure 2E), but there was no significant improvement in survival (Figure 2F), likely due to the regrowth of residual cancer cells.